Ublituximab: Difference between revisions
Content deleted Content added
Undid revision 523730635 by 188.221.143.48 (talk) |
CD20 is the most widely used and best recognised of the many synonyms which are mentioned in the WHO document; MS4A1 page redirects to CD20 page; MS4A1 is the gene name and the antigen is widely called CD20 - the antibody recognises this antigen |
||
Line 7: | Line 7: | ||
| mab_type = mab |
| mab_type = mab |
||
| source = xi/o |
| source = xi/o |
||
| target = [[ |
| target = [[CD20]] |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
Line 46: | Line 46: | ||
}} |
}} |
||
'''Ublituximab''' is an immunomodulator. It binds to [[ |
'''Ublituximab''' is an immunomodulator. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref> |
||
== References == |
== References == |
Revision as of 21:08, 18 November 2012
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider | |
(what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).